You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

404 Results
Guidelines and Advice
Status: Current
Version: 1
Nov 2024
Document
Feb 2025
Document
Feb 2025
Document
Feb 2025
Document
Feb 2025
Document
Feb 2025
Document
Feb 2025
Guidelines and Advice
Status: Current
ID: PET 2024-1
Mar 2025
Document
Apr 2025
Document
May 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Document
May 2025

Pages